Abbott Laboratories is optimistic about the prospects for its neuromodulation technology. It cited the potential for quarterly sequential revenue growth increases over 2019 in neuromodulation and has doubled its R&D investment in the field in order to maximize the and expand upon its pair of neuromodulation products.

Alivecor Inc. has received U.S. FDA clearance for a six-lead ECG known as Kardiamobile 6L. It will start retailing in mid-June for $149 but is available for preorder. This is slated to complement the existing one-lead product Kardiamobile, which sells for $99 and has started to face competition with single-lead ECG watch products from Apple Inc. and Verily Life Sciences LLC.